Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Int J Radiat Oncol Biol PhysMay 3, 2026 (epub)
Jeffrey A Bogart, Xiaofei Wang, Gregory Masters et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the mature outcomes of 61.2 Gy concomitant boost thoracic radiation therapy (CB TRT) in patients with limited-stage small cell lung cancer. After a median follow-up of 115 months, the median overall survival was 32.3 months, and the five-year overall survival rate was 28.5%.
Key findings
- Median overall survival was 32.3 months (95% CI, 20.4-44.8 months).
- Five-year overall survival rate was 28.5% (95% CI, 20.6-39.6).
- Progression-free survival was 15.4 months (95% CI, 10.0-24.0 months).
- Rates of grade 3 and 4 nonhematologic adverse events were 40.9% and 25%, respectively.
Why it matters
The study provides valuable long-term survival data for a specific radiation therapy regimen in limited-stage small cell lung cancer, which may inform treatment decisions and patient counseling regarding expected outcomes.